JP2022536419A5 - - Google Patents

Info

Publication number
JP2022536419A5
JP2022536419A5 JP2021573595A JP2021573595A JP2022536419A5 JP 2022536419 A5 JP2022536419 A5 JP 2022536419A5 JP 2021573595 A JP2021573595 A JP 2021573595A JP 2021573595 A JP2021573595 A JP 2021573595A JP 2022536419 A5 JP2022536419 A5 JP 2022536419A5
Authority
JP
Japan
Prior art keywords
biphenyl
carboxylic acid
ylmethoxy
pyridine
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536419A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037549 external-priority patent/WO2020252353A1/en
Publication of JP2022536419A publication Critical patent/JP2022536419A/ja
Publication of JP2022536419A5 publication Critical patent/JP2022536419A5/ja
Pending legal-status Critical Current

Links

JP2021573595A 2019-06-12 2020-06-12 アミノ酸輸送阻害剤及びその使用 Pending JP2022536419A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860677P 2019-06-12 2019-06-12
US62/860,677 2019-06-12
PCT/US2020/037549 WO2020252353A1 (en) 2019-06-12 2020-06-12 Amino acid transport inhibitors and the uses thereof

Publications (2)

Publication Number Publication Date
JP2022536419A JP2022536419A (ja) 2022-08-16
JP2022536419A5 true JP2022536419A5 (cg-RX-API-DMAC7.html) 2023-06-21

Family

ID=71950790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573595A Pending JP2022536419A (ja) 2019-06-12 2020-06-12 アミノ酸輸送阻害剤及びその使用

Country Status (7)

Country Link
US (1) US20220304984A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983084A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022536419A (cg-RX-API-DMAC7.html)
CN (1) CN114222729A (cg-RX-API-DMAC7.html)
AU (1) AU2020291464A1 (cg-RX-API-DMAC7.html)
CA (1) CA3141405A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020252353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20240174658A1 (en) * 2021-03-01 2024-05-30 Vanderbilt University Heteroaromatic Inhibitors of Cancer Metabolism
WO2024010732A1 (en) * 2022-07-05 2024-01-11 Board Of Regents, The University Of Texas System Small molecule inhibitors of glutamine transporter asct2 and methods of use thereof
CN115894459B (zh) * 2023-01-04 2025-05-27 中国药科大学 一种2-苯并呋喃羧酸衍生物及其制备方法与用途
JP2026508178A (ja) * 2023-02-14 2026-03-10 シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー, リミテッド Nlrp3を阻害する化合物及びその製造方法と応用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
JP4637481B2 (ja) * 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2006034075A1 (en) * 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (hydrazido) (amino) thiophene compounds
AU2005295453A1 (en) * 2004-10-15 2006-04-27 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2297139A1 (en) * 2008-06-20 2011-03-23 Glaxo Group Limited Compounds
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
KR101639642B1 (ko) * 2008-12-05 2016-07-14 애브비 바하마스 리미티드 암 치료에 사용하기 위한 키나제 억제제로서의 티에노[3,2-c]피리딘 유도체
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
WO2011082098A1 (en) * 2009-12-30 2011-07-07 The Rockefeller University Lysine and arginine methyltransferase inhibitors for treating cancer
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US8895607B2 (en) * 2011-07-15 2014-11-25 The University Of Montana Inhibitors of the amino acid transporters ASCT1 and ASCT2
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP2015525781A (ja) 2012-07-31 2015-09-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 免疫応答の調節
WO2014139388A1 (en) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
IL321966A (en) 2013-09-11 2025-09-01 Medimmune Ltd Anti-B7-H1 antibodies for tumor treatment
TW201605857A (zh) * 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Cdk8之醫療性抑制劑及其用途
WO2015132672A2 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
WO2016040527A1 (en) * 2014-09-09 2016-03-17 Vanderbilt University Metabolism probes for therapy and diagnosis
HRP20220237T1 (hr) * 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
WO2018107173A1 (en) * 2016-12-09 2018-06-14 Vanderbilt University Glutamine transport inhibitors and methods for treating cancer
TWI886480B (zh) * 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
CN109369554B (zh) * 2018-10-18 2022-06-17 中国药科大学 一种含有异羟肟酸的取代杂环类化合物及其制备方法和用途
US20240174658A1 (en) * 2021-03-01 2024-05-30 Vanderbilt University Heteroaromatic Inhibitors of Cancer Metabolism

Similar Documents

Publication Publication Date Title
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
JP2023549055A5 (cg-RX-API-DMAC7.html)
JP2022502424A5 (cg-RX-API-DMAC7.html)
JP2016504363A5 (cg-RX-API-DMAC7.html)
JP2011500774A5 (cg-RX-API-DMAC7.html)
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
HRP20240935T1 (hr) Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
JP2021528467A5 (cg-RX-API-DMAC7.html)
EP3875078A1 (en) Compounds for the treatment of covid-19
US20240059703A1 (en) Heterocyclic spiro compounds and methods of use
JP2015504057A5 (cg-RX-API-DMAC7.html)
RU2016111675A (ru) Соединения биарилацетамида и способы их применения
AU2021384833A1 (en) N-(2,3-dihydro-1,4-benzoxazin-4-yl)-3-isopropyl-7-(2,3,5-trifluorophenyl)benzo-thiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections
JP2021519318A5 (cg-RX-API-DMAC7.html)
HRP20211483T1 (hr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka
BG66066B1 (bg) Азаиндоли
EA025520B1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
RU2013136778A (ru) Ингибиторы гистондезацетилазы, композиции и способы их применения
WO2022093856A1 (en) Heterocyclic spiro compounds and methods of use
JP2021512954A5 (cg-RX-API-DMAC7.html)
JP2021501806A5 (cg-RX-API-DMAC7.html)
JP2022502440A5 (cg-RX-API-DMAC7.html)
CN115768762A (zh) 用于治疗亨廷顿氏病的化合物
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP2020511412A5 (cg-RX-API-DMAC7.html)